secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001828185-24-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired
--------------------------------------------------------------------------------

- Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.
- Cash $117.8M at June 30, 2024, down from $130.0M at March 31, 2024; runway into Q2 2026.
- Pipeline prioritized: VTP-300 (HBV) and VTP-1000 (celiac disease); workforce reduction announced.
- Dr. Leon Hooftman appointed Chief Medical Officer effective June 3, 2024.
- Upcoming milestones: VTP-1000 Phase 1 first patient dosing in Q3 2024; HBV data updates in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000073/0001828185-24-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000073/brns-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer